Zhengxi Bio is a developer of in vitro diagnostic reagents and instruments, focusing on the production of high-quality and low-cost monoclonal antibodies, and the production and development of high-end reagents for scientific research and diagnostic flow-based fluorescent antibodies based on proprietary antibodies. It is a biotechnology and in vitro diagnostic company based on four platforms: high-throughput cell culture technology, antibody preparation technology, antibody purification technology, and antibody conjugation technology. Recently completed a new round of financing of tens of millions of yuan. This round of financing was invested by Orient Gene, with Takeshi Capital and Xuyi Capital as financial advisors.
This article is reproduced from: https://www.itjuzi.com/investevent/13270743
This site is for inclusion only, and the copyright belongs to the original author.